FDA

In 2026, an FDA fast track for digital-health AI and Kintsugi’s clearance failure made the agency a central gatekeeper for healthcare software.

Who they are

FDA appears in this coverage as the U.S. regulator whose clearances, authorizations, trial approvals and enforcement role determine whether consumer devices, clinical software and brain-computer interfaces can move into healthcare use. Its recurring role is especially prominent around Apple, Samsung, Google, Neuralink and smaller digital-health developers.

The recent arc

Coverage intensified in the 2024 wearable-health cycle, led by Samsung’s authorization for Galaxy Watch sleep-apnea detection and the FDA’s approval of Apple’s sleep-apnea detection across recent Apple Watch models. Apple’s AirPods Pro 2 hearing-aid feature then became a landmark story: TechCrunch described it as the first over-the-counter hearing-aid software device.

The tension

The coverage circles a persistent trade-off between accelerating health-tech innovation and preserving a credible clinical gatekeeping function. Apple, Samsung and Google have sought regulatory validation for increasingly medical smartwatch features, while Neuralink and Paradromics depend on authorization to test brain implants; Kintsugi’s shutdown after failing to obtain clearance shows that the same threshold can constrain AI-health startups.

Why it matters

If the fast-track approach to digital health continues, FDA decisions could increasingly shape which AI tools become embedded in healthcare and consumer devices, not merely which conventional medical hardware reaches patients. The unresolved question in the coverage is whether quicker pathways can widen access without weakening the evidentiary standards that distinguish medical claims from general-purpose technology.

Related: Apple · the Apple Watch · Neuralink · Samsung · The FDA approves the Hearing Aid Feature in Apple's AirPods Pro 2, cal